Conference Day One
Conference Day One | Wednesday, December 11, 2024
7:20 am Morning Registration & Coffee
8:20 am Chair’s Opening Remarks
Advancing Complement Therapies: Pathways, Clinical Insights & Future Directions
8:30 am Panel Discussion: Dysregulation Insights: An Overview of the Complement System in Health & Human Disease
Synopsis
- Unravelling the 3 complement pathways and potential intervention points
- Understanding core processes in healthy inflammatory response in comparison to pathophysiology of autoimmune conditions
- Discussing the optimal modalities for delivering complement mediated drugs: small molecules, antibodies, and gene therapies
9:00 am The Role of Haem in the Complement System
Synopsis
Haem-binding proteins in regulating complement activation
Pathophysiological mechanisms underlying haem-induced tissue damage
Development of haem-binding proteins or complement inhibitors to prevent haem-mediated complement activation
9:30 am Reserved for Machaon Diagnostics
9:45 am Complement Combinations: Exploring Potential of Complement Inhibitor Combinations in Patients with PNH
Synopsis
- Importance of sustained control of terminal complement activity to prevent the most severe consequences of PNH
- Role of proximal complement inhibition without compromising terminal complement inhibition in patients with PNH
10:15 am Targeting Complement C3 and Factor B with siRNA: Concept to Clinic
Synopsis
- Lessons learned from discovery and early preclinical complement inhibitor studies
- Using Complement Factor B inhibitors to target the alternative pathway
- Evaluating safety, tolerability, PK/PD in C3 and Factor B inhibitors to treat renal disease
10:45 am Speed Networking
Synopsis
This informal session provides the perfect opportunity to connect with the industry frontrunners and key opinion leaders in the complement targeting field. Establish meaningful connections to build upon for the rest of the conference and gain exclusive first-hand insights into the latest research and developments driving progress in modulating, inhibiting and activating the complement system.
11:15 am Morning Break
Optimizing Complement Targeting Strategies: Acute vs. Chronic Inflammation & Homeostasis
11:45 am Panel Discussion: Upstream, Downstream or Proximal – Where, When, & How to Target?
Synopsis
- Discussing acute versus chronic inflammatory disorders and which proteins within the cascade we can target
- Understanding disease progression and debating systemic or tissue specific targeting
- Can combination therapies bridge the gaps and ensure efficacy for treatment?
12:15 pm Reserved for National Jewish Health
Synopsis
12:30 pm GBS vs. GA: Treating Both Acute & Chronic Diseases with C1q Inhibition
Synopsis
- Discussing the efficacy of ANX005 in treating Guillain-Barre Syndrome
- Optimizing dosage for acute and chronic indications
- Summarizing the differences in the challenges of complement inhibition in acute and chronic indications
1:00 pm Lunch Break
Recent Advancements & Exploring When to Pursue RNAi & Gene Therapies
2:00 pm Ligand & Enhancer Assisted Delivery for RNAi Complement Inhibitors
Synopsis
- Targeting C3 with siRNA
- Delivering a GalNAc conjugate to the liver using the LEAD GalNac platform
- Discussing optimal dosage for long-term efficacy
3:00 pm RNAi Therapeutics Coming of Age: Targeting Complement Genes to Treat Rheumatoid Arthritis
Synopsis
- siRNAs to target the “undruggable” candidates and how these fit within the complement cascade
- Considering tissue specific targeting to ensure healthy complement activity remains
- Clinical data updated for the use of siRNA-based complement inhibitors in Rheumatoid Arthritis
3:30 pm Afternoon Break & Poster Session
Synopsis
Immerse yourself in an engaging and informal session, join your peers in a relaxed atmosphere that encourages meaningful conversations and discussions. Explore a range of exciting poster presentations and showcase your own developments in the Complement-Based Drug Development world. Don’t miss out on the chance to submit your own posters and get ready to connect, learn, and present. To submit your poster please contact info@hansonwade.com.
4:00 pm Preclinical Updates for Complement Regulators Using Gene Therapies
Synopsis
- The benefits of using gene therapies to target complement mediated diseases
- Using a localised approach to target the eye and mitigate toxicity
- Updates in targeting Geographic Atrophy/Dry AMD
4:30 pm Roundtable Discussion: Assays, Biomarkers & Computational Modelling in Complement Inhibitor Development
Synopsis
This interactive session gives you the opportunity to be part of the discussion, share ideas and learn from your peers. Choose the table most relevant to you, and get ready to be part of this conversation. Topics to consider:
Improving Reliability &
Making Informed Assay
Choices for Complement
Based Drugs
Validating Qualitative &
Developing Quantitative
Biomarkers for
Complement
Mimicking Mechanistic
Understanding
through Computational
Modelling
Closing this session with an audience wide discussion on enhancing assay reliability, biomarker validation, and computational modelling in complement-based drug development to better standardize comparison of results across the field.